$184.88
0.72% today
Nasdaq, Nov 04, 06:46 pm CET
ISIN
US4576693075
Symbol
INSM

Insmed Incorporated Target price 2025 - Analyst rating & recommendation

Insmed Incorporated Classifications & Recommendation:

Buy
92%
Hold
8%

Insmed Incorporated Price Target

Target Price $147.90
Price $186.23
Deviation
Number of Estimates 20
20 Analysts have issued a price target Insmed Incorporated 2026 . The average Insmed Incorporated target price is $147.90. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 26 analysts: 24 Analysts recommend Insmed Incorporated to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2026 of . Most analysts recommend the Insmed Incorporated stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 363.71 481.71
19.17% 32.44%
EBITDA Margin -214.87% -217.85%
2.97% 1.38%
Net Margin -251.24% -249.79%
2.30% 0.58%

21 Analysts have issued a sales forecast Insmed Incorporated 2025 . The average Insmed Incorporated sales estimate is

$482m
Unlock
. This is
21.00% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$523m 31.38%
Unlock
, the lowest is
$431m 8.14%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $364m 19.17%
2025
$482m 32.44%
Unlock
2026
$1.1b 123.99%
Unlock
2027
$2.1b 90.45%
Unlock
2028
$3.3b 60.73%
Unlock
2029
$4.7b 43.20%
Unlock
2030
$6.2b 31.69%
Unlock
2031
$8.0b 28.35%
Unlock
2032
$9.7b 21.20%
Unlock

8 Analysts have issued an Insmed Incorporated EBITDA forecast 2025. The average Insmed Incorporated EBITDA estimate is

$-1.0b
Unlock
. This is
13.74% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-1.0b 11.05%
Unlock
, the lowest is
$-1.1b 17.37%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-782m 15.63%
2025
$-1.0b 34.28%
Unlock
2026
$-751m 28.48%
Unlock
2027
$-71.5m 90.47%
Unlock

EBITDA Margin

2024 -214.87% 2.97%
2025
-217.85% 1.38%
Unlock
2026
-69.56% 68.07%
Unlock
2027
-3.48% 95.00%
Unlock

22 Insmed Incorporated Analysts have issued a net profit forecast 2025. The average Insmed Incorporated net profit estimate is

$-1.2b
Unlock
. This is
16.33% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-1.1b 6.08%
Unlock
, the lowest is
$-1.2b 20.41%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-914m 21.91%
2025
$-1.2b 31.68%
Unlock
2026
$-776m 35.49%
Unlock
2027
$-271m 65.09%
Unlock
2028
$803m 396.28%
Unlock
2029
$1.8b 125.37%
Unlock
2030
$2.4b 32.50%
Unlock
2031
$3.4b 43.78%
Unlock
2032
$4.5b 31.13%
Unlock

Net Margin

2024 -251.24% 2.30%
2025
-249.79% 0.58%
Unlock
2026
-71.94% 71.20%
Unlock
2027
-13.19% 81.67%
Unlock
2028
24.31% 284.31%
Unlock
2029
38.26% 57.38%
Unlock
2030
38.49% 0.60%
Unlock
2031
43.11% 12.00%
Unlock
2032
46.65% 8.21%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.57 -5.70
4.31% 2.33%
P/E negative
EV/Sales 79.77

22 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is

$-5.70
Unlock
. This is
4.40% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-5.20 4.76%
Unlock
, the lowest is
$-5.90 8.06%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.57 4.31%
2025
$-5.70 2.33%
Unlock
2026
$-3.68 35.44%
Unlock
2027
$-1.28 65.22%
Unlock
2028
$3.80 396.88%
Unlock
2029
$8.57 125.53%
Unlock
2030
$11.36 32.56%
Unlock
2031
$16.33 43.75%
Unlock
2032
$21.41 31.11%
Unlock

P/E ratio

Current -34.11 148.12%
2025
-32.67 4.22%
Unlock
2026
-50.65 55.04%
Unlock
2027
-145.08 186.44%
Unlock
2028
48.97 133.75%
Unlock
2029
21.73 55.63%
Unlock
2030
16.40 24.53%
Unlock
2031
11.41 30.43%
Unlock
2032
8.70 23.75%
Unlock

Based on analysts' sales estimates for 2025, the Insmed Incorporated stock is valued at an EV/Sales of

79.77
Unlock
and an P/S ratio of
82.45
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 96.52 182.06%
2025
79.77 17.36%
Unlock
2026
35.61 55.36%
Unlock
2027
18.70 47.49%
Unlock
2028
11.63 37.78%
Unlock
2029
8.12 30.17%
Unlock
2030
6.17 24.06%
Unlock
2031
4.81 22.09%
Unlock
2032
3.97 17.49%
Unlock

P/S ratio

Current 99.77 179.94%
2025
82.45 17.35%
Unlock
2026
36.81 55.36%
Unlock
2027
19.33 47.49%
Unlock
2028
12.02 37.78%
Unlock
2029
8.40 30.17%
Unlock
2030
6.38 24.06%
Unlock
2031
4.97 22.09%
Unlock
2032
4.10 17.49%
Unlock

Current Insmed Incorporated Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
UBS
Locked
Locked
Locked Oct 31 2025
RBC Capital
Locked
Locked
Locked Oct 31 2025
Goldman Sachs
Locked
Locked
Locked Oct 31 2025
Wells Fargo
Locked
Locked
Locked Oct 31 2025
B of A Securities
Locked
Locked
Locked Oct 27 2025
UBS
Locked
Locked
Locked Oct 14 2025
Goldman Sachs
Locked
Locked
Locked Oct 03 2025
Analyst Rating Date
Locked
UBS:
Locked
Locked
Oct 31 2025
Locked
RBC Capital:
Locked
Locked
Oct 31 2025
Locked
Goldman Sachs:
Locked
Locked
Oct 31 2025
Locked
Wells Fargo:
Locked
Locked
Oct 31 2025
Locked
B of A Securities:
Locked
Locked
Oct 27 2025
Locked
UBS:
Locked
Locked
Oct 14 2025
Locked
Goldman Sachs:
Locked
Locked
Oct 03 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today